aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE) (aTyr or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.
Related news for (LIFE)
- Top Biotech Stocks to Watch Now: Momentum, Milestones & Market Breakouts
- aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
- aTyr Pharma Announces Commencement of Public Offering of Common Stock
- European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis